Piramal Pharma

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA by CARE.
• ResultsLoss-makingLost ₹69 Cr in the Jun 2026 quarter, a smaller loss than a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 35% of the company, about the same as in Jun 2025.
• ValuationNormal for this stockThe share trades at 307.4 times its yearly earnings (P/E), cheaper than 55% of the time in the last 3 years. Its usual P/E is about 316.

Piramal Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)307.4 against a typical 33.2: pricier than most peers (1st = cheapest).210th of 220
• Sales growth+17.4% against a typical +15.6% from a year earlier.91st of 197
• Share price, 3 months+2.1% against a typical −2%.79th of 200
• Size₹ 25,408.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).22nd of 199

Exchange filings and their impact on the company.

• 27 Oct 2026Press ReleaseHigh impactVery positivePrice +15.4% so far today
  Strong H1 with 23% revenue growth and 72% EBITDA growth drives upgraded 19-20% FY27 growth outlook.

  Piramal Pharma reported strong Q2 and H1 FY27 results with Q2 revenue up 28% and H1 up 23%, while EBITDA grew 72% in both periods with over 350 basis points margin expansion. Growth was broad-based with CDMO up 28%, Complex Hospital Generics up 24% and Consumer Healthcare up 14%, supported by 22 new customers and 110 customer audits. Based on strong first-half momentum and a healthy order book, the company upgraded its FY27 outlook to 19-20% revenue growth with meaningfully higher profitability.

  Full analysisFiling
• 27 Oct 2026Outcome of Board MeetingHigh impactPositivePrice +15.4% so far today
  Strong 28% Q2 revenue growth and return to profit point to sustained earnings turnaround.

  Piramal Pharma reported Q2 FY27 consolidated revenue of Rs 2,617 crore, up 28% from last year, and a small net profit of Rs 5 crore versus a Rs 99 crore loss last year. First-half revenue was Rs 4,887 crore, up 23%, with losses narrowing sharply. During the quarter it also raised its stake in Hyderabad-based Yapan Bio to 74% for Rs 76 crore, making it a subsidiary to expand in vaccines and biologics CDMO. The results point to stronger growth and a move toward sustained profitability, though capex and working capital remain high.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Nandini A. Piramal

Executive Chairman of the Board

Vivek Valsaraj

Chief Financial Officer, Executive Director

Maneesh Sharma

Compliance Officer, Company Secretary

Peter DeYoung

Executive Director, Chief Executive Officer of Global Pharma